Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axicabtagene ciloleucel - Kite Pharma

Next Previous
Drug Profile

Axicabtagene ciloleucel - Kite Pharma

Alternative Names: Anti-CD19-CAR-lentiviral-vector-transduced-autologous-T-cells-Kite-Pharma; Anti-CD19-CAR-PBL-Kite-Pharma/NCI; Anti-CD19-CAR-T-cell-therapy-Kite-Pharma/NCI; Anti-CD19-CAR-transduced-T-cells-Kite-Pharma/NCI; Anti-CD19-chimeric-antigen-receptor-lentiviral-vector-transduced-autologous-T-cells-Kite-Pharma; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Kite-Pharma; Anti-CD19-chimeric-antigen-receptor-T-cells-Kite-Pharma/NCI; Anti-CD19-chimeric-antigen-receptor-transduced-T-cells-Kite-Pharma/NCI; anti-human CD19 CAR-T cell injection; Axi-cel®; Ejilunsai injection; FKC 876; KTE-C19; KTE-C19 CAR; YESCARTA; Yescarta; Yi Kai Da; YIKAIDA

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cabaret Biotech
  • Developer Daiichi Sankyo Inc; Genentech; Gilead Sciences K.K.; H. Lee Moffitt Cancer Center and Research Institute; Kite Pharma; Kite Pharma - Fosun Pharma (JV)
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Mantle-cell lymphoma; Follicular lymphoma; B-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Preregistration Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase II Haematological malignancies; Solid tumours
  • No development reported Leukaemia

Most Recent Events

  • 06 Feb 2026 US FDA updates prescription label of axicabtagene ciloleucel in relapsed or refractory Lymphoma
  • 24 Nov 2025 Kite Pharma completes phase II ZUMA-24 clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05459571)
  • 12 Jun 2025 Updated efficacy data from the phase III ZUMA-7 trial in Diffuse B-cell large lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top